TrialA Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Trial details
- Registry ID
- NCT04126681
- Phase
- Phase 2
AAPG
Ascentage Pharma Group Inc.
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
10Trials in this database
8Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceA Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Trial details
- Registry ID
- NCT04496349
- Phase
- Phase 2
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Trial details
- Registry ID
- NCT05147467
- Phase
- Phase 2
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Trial details
- Registry ID
- NCT06051409
- Phase
- Phase 3
Global Trial in APG2575 for Patients With CLL/SLL
Trial details
- Registry ID
- NCT06104566
- Phase
- Phase 3
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Trial details
- Registry ID
- NCT06319456
- Phase
- Phase 3
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Trial details
- Registry ID
- NCT06389292
- Phase
- Phase 3
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Trial details
- Registry ID
- NCT06423911
- Phase
- Phase 3
A Study of Olverembatinib in SDH-deficient GIST.
Trial details
- Registry ID
- NCT06640361
- Phase
- Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Trial details
- Registry ID
- NCT06641414
- Phase
- Phase 3
Latest recorded trial changes
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911 · Ascentage Pharma Group Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: MMR rate Part A
Measure: MMR rate Part B
+ After
Measure: 24-Week MMR Rate (Part A) Measure: 24-Week MMR Rate (Part B)
Planned enrollment increased by 48 participants
− Before
285 participants (planned)
+ After
333 participants (planned)
Primary completion date changed
− Before
Dec 2025
+ After
30 Jun 2027
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566 · Ascentage Pharma Group Inc.
Primary completion date changed
− Before
20 Oct 2025
+ After
31 Dec 2026
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409 · Ascentage Pharma Group Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Minimal residual disease negativity rate
+ After
Measure: Minimal Residual Disease Negative CR Rate
Primary completion date changed
− Before
31 Dec 2024
+ After
31 Dec 2027
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467 · Ascentage Pharma Group Inc.
Primary completion date changed
− Before
Sep 2024
+ After
Dec 2026
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414 · Ascentage Pharma Group Inc.
Planned enrollment increased by 26 participants
− Before
464 participants (planned)
+ After
490 participants (planned)